| Market Capitalization (Millions $) |
75 |
| Shares
Outstanding (Millions) |
75 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
8 |
| Net Income (TTM) (Millions $) |
-32 |
| Cash Flow (TTM) (Millions $) |
-15 |
| Capital Exp. (TTM) (Millions $) |
1 |
Clearside Biomedical Inc
Clearside Biomedical Inc is a biopharmaceutical company focused on developing targeted therapies to treat diseases of the eye. The company utilizes its proprietary technology, known as suprachoroidal space (SCS) injection, to deliver drugs to the back of the eye, specifically targeting the retina and choroid. Clearside's SCS injection technique offers a non-invasive and potentially more effective method of drug delivery compared to traditional methods.
The company's flagship product, XIPERE (formerly known as CLS-TA), is an investigational treatment for macular edema associated with uveitis. XIPERE is designed to be administered via SCS injection, allowing for targeted drug delivery to the affected area of the eye. Clearside also has several other product candidates in its pipeline, including treatments for diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion.
Clearside Biomedical Inc is committed to improving patient outcomes in ophthalmology and is actively conducting clinical trials to assess the safety and efficacy of its therapies. The company's innovative approach to drug delivery and focus on ophthalmic conditions set it apart in the biopharmaceutical industry.
Company Address: 900 North Point Parkway Alpharetta 30005 GA
Company Phone Number: 270-3631 Stock Exchange / Ticker: NASDAQ CLSD
|
2.15%